TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece
Highlights: LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum unit commitment will be negotiated an
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-01 6:45 AM EDT | TempraMed Technologies Ltd.
Herbal Dispatch Reports 2026 Second Quarter Financial Results
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, today reported financial results for the three and six months ended June 30, 2026, highlighted by strong growth in its medical and international businesses, a 74% increase in quarterly gross profit, and an expansion in gross margin to 28.8%
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-09-01 12:14 AM EDT | Herbal Dispatch Inc.
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee. Dr. Duncan is a biotechnology strategist, board director and former top-ranked Wall Street biotechnology anal
2026-08-31 8:00 AM EDT | BetterLife Pharma Inc.
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capabi
Biotechnology, Pharmaceuticals, Health
2026-08-31 3:15 AM EDT | Defence Therapeutics Inc.
Theralase(R) Releases Q2 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released the Company's unaudited interim consolidated financial statements for the six-month period ended Jun
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-28 4:36 PM EDT | Theralase Technologies Inc.
Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
Gaithersburg, Maryland--(Newsfile Corp. - August 28, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (the "Company" or "Shuttle"), today announced that the Company is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission by the required due date. The Co
2026-08-28 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has priced its previously announced public offering (the "Offering") of common shares of the Company ("Commo
2026-08-28 8:00 AM EDT | BetterLife Pharma Inc.
NuGen Announces Filing of Corrective Disclosure Pursuant to OSC Review
Toronto, Ontario--(Newsfile Corp. - August 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") announces that further to the review by the Ontario Securities Commission ("OSC") of the Company's continuous disclosure, the Company has made corrective disclosure with respect to the following: the Company has included in its recently filed management information circular dated August 17, 2026 (the "Circul
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-27 5:30 PM EDT | NuGen Medical Devices Inc.
Vimy Pharmaceuticals Announces Brokered Private Placement of Subscription Receipts
Toronto, Ontario--(Newsfile Corp. - August 26, 2026) - Vimy Pharmaceuticals Inc. ("Vimy Pharma" or the "Company") and Harmony Acquisitions Corp. (TSXV: MONY.P) ("Harmony") are pleased to jointly announce that, further to their press release dated August 6, 2026 announcing the entering into of a non-binding letter of intent to complete a business combination transaction which will constitute a reverse take-over of Harmony (the "Transaction"), Vimy Pharma has launche
2026-08-26 4:18 PM EDT | Vimy Pharmaceuticals Corp.
TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap
Highlights Five-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order. Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain. TempraMed believes t
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-25 7:00 AM EDT | TempraMed Technologies Ltd.
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - August 24, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securitie
2026-08-24 6:42 PM EDT | BetterLife Pharma Inc.
Theralase(R) Closes C$3.6 Million Brokered Financing
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering")
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-24 5:01 PM EDT | Theralase Technologies Inc.
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is plea
Biotechnology, Pharmaceuticals, Health
2026-08-20 9:44 AM EDT | Hemostemix Inc.
Maxwell Biosciences' Spinout SHU.ai Announces Closing of $1M Financing Round
Austin, Texas--(Newsfile Corp. - August 20, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®, December 5, 2025 incorporated its first spinout SHU.ai and June 27, 2026 announced the closing of SHU's $1 million Seed round. The round was oversubscribed and fully funded by private angel investors and led by Keiretsu Forum, "The World's Largest Angel Investor Network." The funds will support accelera
Biotechnology, Pharmaceuticals
2026-08-20 9:00 AM EDT | Maxwell Biosciences, Inc.
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year u
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-20 7:00 AM EDT | TempraMed Technologies Ltd.
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) appli
2026-08-19 8:00 AM EDT | BetterLife Pharma Inc.
Telescope Announces Appointment of Dr. E. Neil Lewis to the Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (the "Company" or "Telescope"), a leading developer of Physical AI systems, including Self-Driving Laboratories, and enabling technologies and services for the global pharmaceutical and high-value chemical industries, is pleased to announce the appointment of Dr. Neil Lewis to its Board of Directors (the "Board"), effective August 19, 2026.
Technology, Chemical, Pharmaceuticals
2026-08-19 8:00 AM EDT | Telescope Innovations Corp.
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and regul
Biotechnology, Pharmaceuticals
2026-08-19 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Richards Group Inc. Announces August 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended August 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on August 31, 2026 and will be payable on September 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-08-18 11:12 AM EDT | Richards Group Inc.
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or
Biotechnology, Pharmaceuticals
2026-08-18 8:00 AM EDT | PharmaTher Holdings Ltd.